Methods for improving respiratory system health and increasing the concentration of hypothiocyanate ion in vertebrate lungs
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11980639-B2
Publication Date
2024-05-14
Expiration Date
Abstract
The present disclosure relates to methods and devices to improve respiratory system health, increase resistance to infection, and increase the hypothiocyanate ion in mammalian lungs. The methods generally comprise: generating a Hydrogen Peroxide Gas that is non-hydrated and free of ozone, and directing the gas comprising primarily Hydrogen Peroxide Gas into an environment and exposing a subject to the environment such that the Hydrogen Peroxide Gas acts to the increase of the hypothiocyanate ion in mammalian lungs.
Core Innovation
The document describes methods for improving respiratory health and treating a respiratory infection in a subject in need by providing an enclosed space for treatment comprising a purified hydrogen peroxide gas (PHPG) that is substantially free of hydration and ozone. The PHPG is present at a final concentration of up to 0.10 ppm in the enclosed space, and the subject is treated by exposing the subject to the enclosed space for at least one period of time to provide a therapeutic amount of PHPG. The treating reduces the severity of the respiratory infection or reduces the duration of the respiratory infection.
The document links inhaled PHPG to increased hypothiocyanate (OSCN−) in mammalian lungs, and explains that OSCN− is formed via lactoperoxidase (LPO)-catalyzed conversion of thiocyanate (SCN−) into OSCN−, including hypothiocyanous acid (HOSCN). It presents PHPG that is non-hydrated and substantially free of ozone as a condition that supports improved innate lung defenses against respiratory infections and chronic lung conditions. The document also provides constraints and definitions for “PHPG free of ozone” and describes operation in enclosed spaces using steady-state PHPG levels.
The document further describes treating humans infected by influenza virus, severe acute respiratory syndrome (SARS) virus, Middle East Respiratory Syndrome (MERS) virus, respiratory syncytial virus (RSV), or the bacterium Streptococcus pneumoniae. It also provides examples reporting reduced illness and improved outcomes with discontinuous PHPG exposure in homes, a baseball team facility, and an individual exposed to a mustard agent.
Claims Coverage
The partial content includes one independent claim (clm-00001), with dependent claims refining exposure timing, repetition frequency, concentration bounds, and symptom-based severity reductions. Across the claim set, the inventive coverage centers on treating respiratory infection by enclosed-space inhalation of ozone- and hydration-substantially-free PHPG at specified concentration and therapeutic exposure conditions.
Enclosed space with ozone- and hydration-substantially-free PHPG
providing an enclosed space for treatment comprising a purified hydrogen peroxide gas (PHPG) that is substantially free of hydration and ozone, wherein said PHPG is present at a final concentration of up to 0.10 parts per million (ppm) in said enclosed space
Exposing infected subject to provide therapeutic amount of PHPG
treating said subject in need by exposing said subject to said enclosed space for at least one period of time to provide a therapeutic amount of PHPG, wherein said subject in need has a respiratory infection, wherein said treating reduces the severity of the respiratory infection or reduces the duration of the respiratory infection
Human infected with selected respiratory pathogens
wherein said subject in need is a human and is infected by an influenza virus, a severe acute respiratory syndrome (SARS) virus, a Middle East Respiratory Syndrome (MERS) virus, a respiratory syncytial virus (RSV), or the bacterium Streptococcus pneumoniae
Together, the claims cover enclosed-space delivery of PHPG that is substantially free of hydration and ozone at a final concentration of up to 0.10 ppm, followed by exposing a human with a respiratory infection for at least one period of time to provide a therapeutic amount that reduces severity or duration, including specified viral and bacterial infections.
Stated Advantages
Reducing the severity of the respiratory infection.
Reducing the duration of the respiratory infection.
Improving respiratory health by increasing hypothiocyanate (OSCN−) in mammalian lungs.
Documented Applications
Discontinuous PHPG exposure in homes, including reports of reduced illness and improved outcomes.
Discontinuous PHPG exposure in a baseball spring training facility, with reported improved outcomes.
Exposure of an individual to a mustard agent, with reported improved outcomes associated with PHPG exposure.
Interested in licensing this patent?